Neiry Group announces the start of patient recruitment for participation in a scientific study on the treatment of pharmacoresistant obsessive-compulsive disorder (OCD) and pharmacoresistant depression using deep brain stimulation.
Patients who pass the screening process will undergo a surgical procedure to implant thin electrodes into brain regions associated with symptoms of pharmacoresistant OCD and characterized by altered activity. The electrodes will then be connected to a small device — a pulse generator. This device will deliver targeted stimulation to specific brain areas, which is expected to reduce symptom severity by at least one-third.
In the future, Neiry intends to study the effectiveness of neuromodulation in rehabilitation after stroke, spinal cord injuries, as well as in the treatment of erectile dysfunction. In addition, the team plans to use neuromodulation for the treatment of incontinence, chronic pain, migraine, Parkinson’s disease, epilepsy, essential tremor, and other conditions.
Patients who pass the screening process will undergo a surgical procedure to implant thin electrodes into brain regions associated with symptoms of pharmacoresistant OCD and characterized by altered activity. The electrodes will then be connected to a small device — a pulse generator. This device will deliver targeted stimulation to specific brain areas, which is expected to reduce symptom severity by at least one-third.
In the future, Neiry intends to study the effectiveness of neuromodulation in rehabilitation after stroke, spinal cord injuries, as well as in the treatment of erectile dysfunction. In addition, the team plans to use neuromodulation for the treatment of incontinence, chronic pain, migraine, Parkinson’s disease, epilepsy, essential tremor, and other conditions.
